Examkin

Question

Difficulty: HardDiagnostic Workup and Test Sequencing

A patient with a known history of primary hyperparathyroidism presents with severe, refractory heartburn and chronic watery diarrhea. Endoscopic evaluation performed recently by an outside gastroenterologist demonstrated severe erosive esophagitis and prominent, multiple ulcerations extending into the second and third portions of the duodenum. The patient is currently taking 80 mg of pantoprazole daily with minimal symptom relief. The clinical team strongly suspects a gastrinoma associated with Multiple Endocrine Neoplasia type 1 (MEN1). Arrange the following diagnostic steps in the most appropriate chronological sequence to biochemically confirm the diagnosis and subsequently localize the tumor.

  1. 1Discontinue proton pump inhibitor therapy and substitute with a histamine-2 receptor antagonist temporarily
  2. 2Measure simultaneous fasting serum gastrin and gastric pH
  3. 3Perform an intravenous secretin stimulation test
  4. 4Obtain a Gallium-68 DOTATATE PET/CT scan
  5. 5Perform an endoscopic ultrasound (EUS) of the pancreas and duodenum

Answer

The correct diagnostic sequence begins with discontinuing the proton pump inhibitor, followed by measuring fasting serum gastrin with gastric pH. A secretin stimulation test is then performed to biochemically confirm Zollinger-Ellison syndrome. Once confirmed biochemically, localization is achieved first with a non-invasive Gallium-68 DOTATATE PET/CT, followed by an endoscopic ultrasound.
The diagnostic workup of Zollinger-Ellison syndrome requires a strictly tiered approach, moving from baseline preparation to biochemical confirmation, and finally to anatomical localization. Because proton pump inhibitors cause secondary hypergastrinemia, they must be stopped prior to testing to avoid false-positive results. The initial screening step requires assessing fasting serum gastrin alongside gastric pH to confirm acidic hypergastrinemia. If the gastrin level is elevated but not strongly diagnostic, a secretin stimulation test is required for definitive biochemical confirmation. Only after the biochemical diagnosis is secure should localization studies be pursued. Non-invasive, highly sensitive functional imaging such as a Gallium-68 DOTATATE PET/CT is the initial imaging modality of choice. Finally, endoscopic ultrasound is utilized for precise localization of small tumors within the duodenal wall or pancreas, and for obtaining a required tissue biopsy.

Step-by-Step Solution

1
Prepare for biochemical testing.
Discontinue pantoprazole therapy.
Proton pump inhibitors cause physiologic hypergastrinemia via loss of negative feedback. Testing while on a PPI will yield uninterpretable or falsely positive gastrin levels.
2
Screen for acidic hypergastrinemia.
Check fasting serum gastrin and gastric pH simultaneously.
A markedly elevated gastrin in the presence of acidic pH (pH < 2) suggests a gastrinoma, differentiating it from achlorhydria (where pH is alkaline).
3
Confirm the diagnosis biochemically.
Administer the secretin stimulation test.
Normal G cells are inhibited by secretin, whereas gastrinoma cells paradoxically release gastrin in response to secretin, confirming Zollinger-Ellison syndrome when initial gastrin values are equivocal.
4
Perform initial functional localization.
Obtain somatostatin receptor imaging (PET/CT).
This is a highly sensitive, non-invasive modality for detecting primary neuroendocrine tumors and staging distant metastases.
5
Achieve precise anatomical localization.
Perform endoscopic ultrasound (EUS).
Provides high-resolution imaging of the gastrinoma triangle and allows for fine-needle aspiration tissue sampling prior to definitive surgical resection.

Key Concept

The diagnostic workup of Zollinger-Ellison syndrome requires securing a definitive biochemical diagnosis (off acid-suppressive therapy) prior to pursuing localization imaging.
Rate this question

Topics

Diagnostic Workup and Test Sequencing

More questions from this topic